SCHEMBL4974686

SCHEMBL4974686

O=C(Nc1ccc(C(F)(F)C(F)(F)F)c(OC[C@@H]2CCCN2)c1)c1cccnc1NCc1ccnc2[nH]ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 8/20 0.40
KDR P35968 7/20 0.39
PDPK1 O15530 2/20 0.38
FLT3 P36888 2/20 0.37
NTRK1 P04629 1/20 0.37
CIT O14578 1/20 0.36
MAP3K7 O43318 1/20 0.36
RIPK2 O43353 1/20 0.36
STK10 O94804 1/20 0.36
MAP4K4 O95819 1/20 0.36
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
RAF1 P04049 1/20 0.36
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
CSF1R P07333 1/20 0.36
YES1 P07947 1/20 0.36
LYN P07948 1/20 0.36
RET P07949 1/20 0.36
HCK P08631 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4974491 0.87 KDR (0.45) METKDRPDPK1FLT3NTRK1
SCHEMBL445790 0.85 KDR (0.55) KDRFLT3CITMAP3K7RIPK2
SCHEMBL187830 0.85 KDR (0.55) KDRFLT3CITMAP3K7RIPK2
SCHEMBL6013568 0.85 KDR (0.55) KDRFLT3CITMAP3K7RIPK2
SCHEMBL4977912 0.85 KDR (0.44) METKDRPDPK1FLT3NTRK1
SCHEMBL4975078 0.85 KDR (0.44) METKDRPDPK1FLT3NTRK1
SCHEMBL6106380 0.85 KDR (0.46) KDRPDPK1FLT3CITMAP3K7
SCHEMBL6104030 0.85 KDR (0.46) KDRPDPK1FLT3CITMAP3K7
SCHEMBL5012043 0.85 MEN1 (0.43) METKDRPDPK1BRAFFLT1
SCHEMBL4973509 0.85 MEN1 (0.43) METKDRPDPK1BRAFFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971604-B1 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC (US) 2012-08-01 EP claimed
EP-1971604-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES Amgen Inc. (US) 2008-09-24 EP claimed
US-20070185171-A1 Compounds and methods of use AMGEN INC. 2007-08-09 US claimed
WO-2007048070-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC. (US) 2007-04-26 WO claimed
US-8247556-B2 Method for preparing 6-substituted-7-aza-indoles AMGEN INC. (US) 2012-08-21 US disclosed
US-8247556-B2 Method for preparing 6-substituted-7-aza-indoles AMGEN INC. (US) 2012-08-21 US disclosed
US-8247556-B2 Method for preparing 6-substituted-7-aza-indoles AMGEN INC. (US) 2012-08-21 US disclosed
EP-1971604-B1 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC (US) 2012-08-01 EP disclosed
EP-1971604-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES Amgen Inc. (US) 2008-09-24 EP disclosed
US-20070185171-A1 Compounds and methods of use AMGEN INC. 2007-08-09 US disclosed
US-20070185171-A1 Compounds and methods of use AMGEN INC. 2007-08-09 US disclosed
US-20070185171-A1 Compounds and methods of use AMGEN INC. 2007-08-09 US disclosed
WO-2007048070-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185171-A1 Compounds and methods of use VHL, PGF, PTGIS MET 994/4885KDR 59/4885PDPK1 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.